Marnie Hoolahan is the Managing Director of The Nemetz Group.

Marnie Hoolahan


Marnie brings her energy, dynamic personality, problem-solving skillset, and can-do attitude to every challenge. Her depth and breadth across the development and commercialization continuum bring a unique and refreshing perspective to her clients and budding entrepreneurs. Her direct, candid, and honest insights make her a sought out thought partner for executives.

Marnie joined The NemetzGroup in 2011, contributing over 25 years of biopharma executive-level consulting and industry experience in corporate strategy, sales, new product planning, and business development to our team and clients. Marnie’s focus has been on rare disease clients and has led a variety of Corporate, Medical Affairs, and Commercial engagements. Marnie co-authored two industry submissions to NORD (2018) on behalf of her client, X4 Pharmaceuticals, and has authored several of The NemetzGroup e-conversations.

Prior to joining The NemetzGroup, Marnie served in various roles at Genzyme Corporation, most recently as a Vice President of Business Excellence and Commercial Assessment. Marnie has also held many positions of increasing responsibility at the sales and management levels at BMS and Geltex.

Marnie Hoolahan is a member of the Life Science Cares Board of Advisors and provides Wyss Institute PhD entrepreneurs with pragmatic training for pitching their science to investors. She earned a Bachelor of Science in Marketing from Boston College and an MBA in Entrepreneurial Business and Finance from Babson College.